Sanjiv Gangaram-Panday, PhD, discusses findings from a population-based cohort study of definitive chemoradiotherapy in esophageal adenocarcinoma.
Sanjiv Gangaram-Panday, PhD
Advertisement
Sanjiv Gangaram-Panday, PhD,of Erasmus University Rotterdam
Articles by Sanjiv Gangaram-Panday, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5